Transgene S.A.
TNG
Classement en actions
#17543
Transgene SA, a French biotechnology firm headquartered in... Transgene SA, a French biotechnology firm headquartered in Illkirch-Graffenstaden, specializes in designing and developing groundbreaking therapeutic vaccines and oncolytic viruses to combat cancer and infectious diseases. Founded in 1979 and operating as a subsidiary of TSGH SAS, the company maintains a robust pipeline of treatments. This includes TG4050, a therapeutic vaccine in Phase I clinical trials for ovarian cancer and HPV-negative head and neck cancers, and TG4001, another therapeutic vaccine currently in Phase II for HPV-positive cancers. Its oncolytic virus programs feature TG6002, undergoing Phase I/IIa trials for various solid tumors, specifically gastrointestinal adenocarcinomas impacting the stomach, pancreas, and colon, as well as BT-001, an oncolytic virus in Phase I/II for solid tumors. Furthermore, Transgene is progressing TG1050, a therapeutic vaccine for chronic hepatitis B, and Pexa-Vec, an oncolytic virus targeting solid tumors. The company has established a comprehensive network of partnerships, encompassing strategic collaborations with major players like AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation, alongside licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva, and additional agreements with Sanofi, BioInvent, and Randox.
Prix de l'action
$0.81133014
Capitalisation boursière
$225.76M
Changement (1 jour)
-0.58%
Changement (1 an)
-46.06%
Pays
FR
Échange Transgene S.A. (TNG)
Catégorie
Healthcare
Capitalisation boursière de Transgene S.A.(TNG)
Capitalisation boursière: $225.76M
En October 2026, Transgene S.A. a une capitalisation boursière de $225.76M. Cela fait de Transgene S.A. la 17543rd entreprise la plus valorisée au monde selon nos données. La capitalisation boursière, souvent appelée market cap, correspond à la valeur totale des actions en circulation d’une entreprise cotée en bourse, et est couramment utilisée pour évaluer sa valeur.
Historique de la capitalisation boursière de Transgene S.A. du 2008 au 2026
TNG par rapport au top 5 des plus populaires stocks
| Prix pour TNG | L’actif B | La capitalisation boursière de B | Résultats | |
|---|---|---|---|---|
$36,253.62
$116.99M
|
$5.228T | +4,468,317.76% | ||
|
$34,992.63
$116.99M
|
$5.046T | +4,312,895.63% | ||
|
$28,903.93
$116.99M
|
$4.168T | +3,562,436.71% | ||
|
$27,388.90
$116.99M
|
$3.949T | +3,375,702.10% | ||
|
$19,207.39
$116.99M
|
$2.770T | +2,367,295.51% |
